semaglutide alcohol use disorder Active ingredient in Ozempic, Wegovy shows early promise for treating among those with obesity: Study Semaglutide and Tirzepatide reduce alcohol

regulatory and safety overview Endocrinology (OUP) Effects of hGH and AOD9604 on lipid metabolism in obese mice

Novo Nordisk (NVO): In 2023, Novo Nordisk announced the results from its SELECT trial that showed that semaglutide was associated with a 20% decreased risk of major adverse cardiac events comprised of cardiovascular death, nonfatal myocardial infarction (MI), and stroke compared with placebo in patients with overweight or obesity and established CVD but without diabetes

Pure, well-absorbed glutathione delivers better results than higher doses of low-quality supplements

30 , 44734489.e5 (2020)

Gradual, slight variation between batches is normal

While very rare, more serious side effects like pancreatitis or gallbladder issues have been reported